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Anomalous expression of the Rh antigen, D, has occasion-
ally been observed in patients with certain myeloproliferative 
disorders.  Indeed, this phenomenon led to the tentative 
assignment of RH to the short arm of chromosome 1.  PCR-
based analyses were performed on DNA from an 82-year-old 
D+ Caucasian patient with chronic myeloid leukemia after her 
RBCs became D–.  For nearly 7 years, the patient’s RBCs typed 
as strongly D+, but in March 2006, they typed weakly D+ and 
in August 2006 typed D– by both direct hemagglutination and 
the IAT.  The D– typing persisted until the patient’s death in 
September 2006.  To study the underlying cause of the change 
in D type, PCR-based assays were performed on DNA extracted 
from peripheral WBCs from the patient’s sample collected in 
August 2006.  No amplification was obtained using primers 
designed to amplify RHD exons 5, 8, or 10, and intron 4.  Very 
weak amplification was obtained using primers designed 
to amplify RHD exons 3, 4, or 7.  Two assays that detect the 
hybrid Rhesus box showed deletion of RHD.  Amplification of 
RHCE in the patient’s DNA was as efficient as that of control 
samples, and multiplex and PCR-RFLP assays predicted her 
RBCs would be C–E–c+e+.  Based on finding a hybrid Rhesus 
box and absence of D-specific exons, we conclude that DNA 
from the patient’s WBCs carries a deleted RHD.  This explains 
the molecular mechanism underlying the change from D+ to 
D–.  Immunohematology 2008;24:160–164.
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Rh antigens are generally considered to be 
stable.  Nonetheless, abnormal expression of some 
Rh antigens, notably D, has occasionally been ob-
served in patients with certain myeloproliferative 
disorders, including chronic myeloid leukemia (CML). 
Although this phenomenon is usually associated 
with the presence of two RBC populations of dif-
ferent Rh phenotype in a patient’s peripheral blood, 
a few patients have a complete loss of certain Rh 
antigens.  As early as 1974, this phenomenon led to 
the tentative assignment of RH to the short arm of 
chromosome 1.1  Later studies showed this to be true 
when the RH locus was assigned to chromosome 
1p36.1.2,3  One D+ patient with myeloid metaplasia 
became D– owing to a chromosome translocation, 
and actually made anti-D plus anti-C.4  In another 
D+ patient with CML whose RBCs became D–, DNA 
analysis revealed a mutation within the RHD: a single 
nucleotide deletion (600Gdel) caused a frameshift 
that silenced RHD.5
To determine the underlying cause of the change 
in D type, we performed PCR-based analyses on DNA 
from a D+ patient with CML after her RBCs became 
D–.  The patient had no evidence of a chromosome 
translocation and had not received a transplant.  The 
results showed a remarkably precise deletion of 
RHD.
Case Study
The patient was an 82-year-old Caucasian female 
with CML.  For nearly 7 years (May 1999 through 
February 2006), the patient’s RBCs typed as strongly 
D+ (3+).  During these dates, no other Rh antigen typ-
ings were performed and O+ RBC components were 
transfused.  In March 2006, the patient’s RBCs typed 
weakly D+ (1+) and she was transfused with two units 
of O+ packed RBC components.  In August 2006, they 
typed D– with seven examples of reagent anti-D both 
by direct hemagglutination and by the IAT.  At this 
time, her RBCs typed as C–E–c+e+.  Repeat testing 
on the same sample and on a freshly collected sample 
confirmed the D– status of her RBCs.  Furthermore, 
D– typings (by direct testing and IAT) were obtained 
on eight samples collected on different occasions 
between August and September 2006.  From August 
2006 until her death the patient was transfused with 
O– RBC components; she did not develop anti-D. 
Chromosome analysis was performed and showed 
no evidence of a chromosome translocation, and the 
patient had not received a stem cell transplant.  To 
study the underlying cause of the change in D type, 
PCR-based assays were performed on DNA extracted 
from peripheral WBCs from the patient’s sample 
collected in August 2006.  Unfortunately, the patient 
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died before we could obtain somatic cells (buccal 
epithelial cells, urine sediment, hair root, or tissue 
from an earlier biopsy) for extraction of DNA.
Materials and Methods
Genomic DNA Extraction
Genomic DNA was extracted using a DNA extrac-
tion kit (QIAamp DNA Blood Mini Kit, QIAGEN, Inc., 
Valencia, CA) from peripheral WBCs.
PCR Amplification of RHD and RHCE
RHD and RHCE were amplified using sev-
eral primer pairs, which were synthesized by Life 
Technologies, Inc. (Gaithersburg, MD).  Primer 
sequences, expected amplicon sizes, and annealing 
temperature are shown in Table 1.  Five microliters of 
genomic DNA were amplified with 5 U of Taq DNA 
polymerase (HotStarTaq, QIAGEN, Inc.) in a 50-μL 
reaction mixture containing 1× PCR buffer, 0.2 mM 
dNTPs, 100 ng both primers, and specific magnesium 
chloride as listed in Table 1.  PCR amplification was 
performed in a thermal cycler (Model 97000, Perkin 
Elmer, Norwalk, CT) under the following conditions: 
35 cycles of 94°C for 20 seconds, 60°C, 62°C, or 64°C 
for 20 seconds, and 72°C for 20 seconds, followed by 
a final extension of 10 minutes at 72°C. PCR products 
were analyzed on a 1.2% agarose gel.  A multiplex 
assay for RHD and RHCE*C/c was performed,6 and 
Table 1. Primers used for PCR analyses
  Amplicon Region MgCl2 Concentration 
    and Annealing 
Primer Name Primer Sequence Size  Temperature
RHDCEX3F 5´-TATTCGGCTGGCCACCATGA-3´ 470 bp RHD 2.5 mM 
   Exon 3 60°C
RHI3R 5´-ATGTTGCCCAGCTCGGTCC-3´
RHDI3S 5´-GGCTTGCCCCGGGCAGAGG-3´ 321 bp RHD 1.5 mM 
   Exon 4 64°C
RHDI4AS 5´-GCTTCAGACACCCAGGGGAAC-3´
RHDI4 5´-TAAGCACTTCACAGAGCAGG-3´ 423 bp RHD 3.0 mM 
   Exon 5 64°C
SK44 5´-GAGCCGATAACGCGTCCATCG-3´
HincD3R 5´-GAGCCGATAACGCGTCCATCGGTCGACCTTGCTGATCTTCCCTTGG-3´
RHDARX7F 5´-ACAGCTCCATCATGGGCTACAA-3´ 262 bp RHD 3.0 mM 
   Exon 7 60°C
RHDCEInt7R 5´-CTGGACAGAATTTCTGAATAAATC-3´
RHDI7F 5´-CTGGAGGCTCTGAGAGGTTGAG-3´ 516 bp RHD 2.5 mM 
   Exon 8 62°C
RHDI8R 5´-CATAGACATCCAGCCACACGGCA-3´
CEI4 5´-GGCAACAGAGCAAGAGTCCA-3´ 474 bp RHCE 1.5 mM 
   Exon 5 60°C
CEX5 5´-CTGATCTTCCTTTGGGGGTG-3´
Ex10F 5´-TTTCCTCATTTGGCTGTTGGATTTTAA-3´ RHD: 245 bp RHD and RHCE 3.0 mM 
  RHCE: 160 bp Exon 10 58°C
RHD3UT 5´-GTATTCTACAGTGCATAATAAATGGTG-3´
RHCE3UT 5´-CTGTCTCTGACCTTGTTTCATTATAC-3´
RHI41 5´-GTGTCTGAAGCCCTTCCATC-3´ RHD: 115 bp RHD and RHCE 1.5 mM 
  RHCE: 233bp Intron 4 62°C
RHI42 5´-GAAATCTGCATACCCCAGGC-3´
RHI43 5´-ATTAGCTGGGCATGGTGGTG-3´
Rh-Hyb2-U 5´-caaaaccattttttcctgagac-3´ RHD deletion: RHD upstream 2.0 mM 
  1.5kb and downstream 54°C
Rh-Hyb2-L 5´-aattaatggctttcattatcgg-3´
  HGH: 429bp
HGH-F 5´-GCCTTCCCAACCATTCCCTTA-3´
HGH-R 5´-TCACGGATTTCTGTTGTGTTTC-3´
Rh-Rez-7 5´-cctgtccccatgattcagttacc-3´ 3kb RHD upstream 1.5 mM 
   and downstream 58°C and 59°C
Rh-Rnb-31 5´-cctttttttgtttgtttttggcggtgc-3´
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RHCE*E/e was analyzed by an allele-specific PCR-
RFLP assay as described.7
Assays for the Presence of RHD Deletion
RHD zygosity was determined by PCR detection 
of the hybrid Rhesus box8 and by PCR-RFLP with 
PstI.9  For the hybrid Rhesus box assay, PCR reactions 
were carried out in a total volume of 50 μL and con-
tained 200 ng of genomic DNA, 1× PCR buffer, 2 mM 
MgCl2, 0.2 mM dNTPs, 10 µM of RH primers, and 2.5 
µM of the human growth hormone (HGH) control 
primers, and 1 U of Taq DNA polymerase (QIAGEN, 
Inc).  PCR amplification was performed in a thermal 
cycler (Model 2720, Perkin Elmer) under the follow-
ing conditions: 30 cycles of 94°C for 30 seconds, 54°C 
for 45 seconds, and 72°C for 90 seconds, followed 
by a final extension of 5 minutes at 72°C.  For the 
PCR-RFLP PstI assay, PCR reactions were carried out 
in a final volume of 50 μL and contained 200 ng of 
genomic DNA, 1× PCR buffer, 1.5 mM MgCl2, 0.2 mM 
dNTPs, 15 µM each primer, and 2.5 U of HotStar Taq 
DNA polymerase (QIAGEN, Inc).  PCR amplifications 
were performed under the following conditions: 10 
cycles of 94°C for 15 seconds, 58°C for 30 seconds, 
and 72°C for 120 seconds and 25 cycles of 94°C for 
15 seconds, 59°C for 30 seconds, and 72°C for 120 
seconds plus 5 seconds each cycle, followed by a 
final extension of 7 minutes at 72°C.  PCR products 
were separated on 2% agarose gels and visualized by 
ethidium bromide staining.
Results
Amplification of RHD and RHCE
No amplification was obtained using primers 
designed to amplify RHD exons 5, 8, and 10, and 
intron 4.  Weak amplification was obtained using 
primers designed to amplify RHD exons 3, 4, or 
7.  Repeat testing gave identical results.  Using the 
same primers, in a D-positive control, RHD ampli-
fied as expected, and in a D-negative control did not 
amplify.  Representative results are shown in Figure 
1.  Amplification of RHCE in the patient’s DNA was 
as efficient as that of control samples.  Multiplex 
and PCR-RFLP assays predicted her RBCs would be 
C–E–c+e+ (not shown).
Assays for Rhesus Box
To further investigate the loss of D expression, 
an assay that detects the hybrid junction associated 
with the RHD deletion6 was performed.  The assay 
was positive, indicating the patient had at least one 
RHD deletion.  To further determine zygosity, a sec-
ond assay was done9 to amplify a region termed the 
hybrid Rhesus box.  Digestion of the products with 
the restriction enzyme PstI gave a pattern consistent 
with samples homozygous for an RHD deletion (Fig. 
2).  These results confirm that the D-negative pheno-
type in this patient was associated with homozygous 
deletion of RHD.
To confirm the myeloid or somatic nature of this 
deletion would require analyses of DNA extracted 
from somatic cells.  Unfortunately, the patient died 
before additional blood samples and a buccal smear 
as a source of somatic DNA could be obtained.
Discussion
At the time the patient’s RBCs typed D–, DNA 
extracted from her WBCs showed deletion of RHD 
and an apparently normal RHCE*ce.  As the patient 
was Caucasian, she is more likely R0r than R0R0, and 
if so, the RHD was deleted from the chromosome 
carrying R0.  This is the first report of DNA testing on 
a patient whose RBCs changed from D+ to D–, show-
ing that the underlying cause is a specific deletion of 
Fig. 1. Representative gels after PCR amplification.  The 100-bp DNA 
ladder is shown, as are the patient (CML Proband), positive 
control (R1R1), and negative control (rr).  The first three lanes 
show strong amplification of exon 5 of RHCE in the patient 
and, as expected, in the D-positive and D-negative controls. 
The second three lanes show amplification of exon 3 of RHD, 
which is weak in the patient, strong in the D-positive control, 
and absent from the D-negative control.  The last three lanes 
show no amplification in the patient and D-negative control 
and strong amplification in the D-positive control of exon 5 of 
RHD.
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RHD.  This mechanism is summarized in Figure 3. 
As we were unable to obtain DNA from somatic cells 
from this patient, we encourage others to study RHD 
and the hybrid Rhesus box in other such patients to 
determine whether deletion of RHD occurs spe-
cifically in hematopoietic cells.  A recent paper by 
Kormoczi and coworkers10 describes a multi-tech-
nique approach to study nine patients with coexisting 
D+ and D– RBCs not attributable to transfusion, 
transplantation, or natural chimerism.  In each case, 
their findings indicated myeloid-restricted loss of dif-
ferent stretches of the short arm of chromosome 1 
(in one case the long arm of chromosome 1 was also 
involved), all of which encompassed the RHD/RHCE 
gene locus.  Based on this study, loss of a part of 
chromosome 1, especially the short arm, is not as 
uncommon as previously believed.
In the case described here, the presence of the 
hybrid Rhesus box demonstrates the deletion of 
RHD, and the amplification obtained with some 
primer pairs shows the presence of low levels of 
RHD.  Deletion of RHD but not RHCE demonstrates 
the precise nature of these events and provides in-
sight into the role of the Rhesus boxes (which flank 
RHD but not RHCE) in the deletion of RHD in most 
D– Caucasians.  This may provide an explanation as 
to why deletion of RHCE has not been observed.
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